In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor

被引:51
|
作者
Singh, Pushpendra [1 ]
Bast, Felix [1 ]
机构
[1] Cent Univ Punjab, Ctr Biosci, Sch Basic & Appl Sci, Bathinda 151001, Punjab, India
关键词
Cancer; Epidermal growth factor receptor; Mutation; Natural compound; Maestro 9.3 (Schrodinger 2012); CELL LUNG-CANCER; PROSTATE-CANCER; KINASE INHIBITORS; TYROSINE KINASES; ANDROGEN RECEPTOR; ACCURATE DOCKING; DOWN-REGULATION; T790M MUTATION; EGFR T790M; GEFITINIB;
D O I
10.1007/s00044-014-1090-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The role played by overexpression of tyrosine kinase epidermal growth factor receptor (EGFR), the transmembrane receptor central to numerous cellular processes comprising cell migration, adhesion, apoptosis, and cell proliferation, has been highlighted in various cancers such as prostate, breast, lung, and ovarian cancers as well as in mutations in the EGFR kinase domain. Although many therapeutic approaches have targetted EGFR, the mutations occurring in the EGFR kinase domain including L858 EGFR and T790/L858R had led to the amplification of EGFR signals, consequently leading to increased cell proliferation and cell growth. The strategies involving the inhibition of EGFR L858 and T790M have been accredited with limited achievement in addition to being associated with unwanted adverse effects as a result of crosstalk of wild-type EGFR. All current EGFR tyrosine kinase inhibitors have been identified as ATP competitive inhibitors of wild-type EGFR possessing aniline and quinazoline moiety on the ligands skeleton. Our results obtained by performing molecular docking study on Maestro 9.3 molecular docking suite indicated that CID5280343 possesses better energy conformation against wild-type EGFR as well as two mutated EGFR. Moreover, it was discovered in this study that the natural compounds CID72276, CID5280445, CID441794, and CID72277 and InterBioScreen's library STOCK1N-78657, STOCK1N-78976, and STOCK1N-78847 have better binding conformation against gatekeeper T790M mutated EGFR concluded to be brought about by means of flexible ligands/receptor-based molecular docking protocol. Miraculous features of these compounds are their various pharmacokinetic and pharmacodynamic parameters which were found to be satisfactory as drug-like molecules. This molecular docking study also summarizes docking free energy, protein-ligands interaction profile, and pharmacokinetic and pharmacodynamic parameter of lead molecules which were tremendously helpful in enhancing the activity of these natural compounds against EGFR.
引用
收藏
页码:5074 / 5085
页数:12
相关论文
共 50 条
  • [31] Mitochondrial toxicity of selected natural compounds: in vitro assessment and in silico molecular docking and dynamics simulation
    Erguc, Ali
    Albayrak, Gokay
    Muhammed, Muhammed Tilahun
    Karakus, Fuat
    Arzuk, Ege
    DRUG AND CHEMICAL TOXICOLOGY, 2025, 48 (01) : 199 - 209
  • [32] In Silico Analysis and Molecular Docking Studies of Novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one Derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Panchal, Ishan I.
    Shah, Ashish
    Devgirkar, Animesh
    Shah, Umang
    Patel, Ashish
    Patel, Alkesh
    Sen, Dhrubo J.
    CURRENT CANCER THERAPY REVIEWS, 2019, 15 (03) : 235 - 247
  • [33] Immunohistochemical study of estradiol, epidermal growth factor, transforming growth factor alpha and epidermal growth factor receptor in endometrial neoplasia
    Yokoyama, Y
    Takahashi, Y
    Hashimoto, M
    Morishita, S
    Tamaya, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (06) : 411 - 416
  • [34] Molecular docking and interactions between vascular endothelial growth factor (VEGF) receptors and phytochemicals: An in-silico study
    Lutfiya, A. Shirin
    Priya, S.
    Manzoor, Muhammed A. P.
    Hemalatha, S.
    BIOCATALYSIS AND AGRICULTURAL BIOTECHNOLOGY, 2019, 22
  • [35] In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2
    Megantara, Sandra
    Wathoni, Nasrul
    Mohammed, Ahmed Fouad Abdelwahab
    Suhandi, Cecep
    Ishmatullah, Maryam H.
    Putri, Melisa F. F. D.
    POLYMERS, 2022, 14 (13)
  • [36] Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice
    Schroeder, Carsten
    Gower-Page, Craig
    Reyes-Rivera, Irmarie
    Patel, Arisha
    Price, Richard
    Sen, Shiraj
    Davies, Jessica
    Castellanos, Emily
    Snider, Jeremy
    Bai, Xiaobo
    Fisher, Virginia
    Mhatre, Shivani K.
    JCO CLINICAL CANCER INFORMATICS, 2022, 6
  • [37] Studies of natural polyphenols as potential epidermal growth factor receptor inhibitors
    Starok, M. A.
    Nowacki, L.
    Vayssade, M.
    Hano, C.
    Haupt, K.
    Rossi, C.
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2013, 42 : S183 - S183
  • [38] Potential of Epidermal Growth Factor-like Peptide from the Sea Cucumber Stichopus horrens to Increase the Growth of Human Cells: In Silico Molecular Docking Approach
    Pilus, Nur Shazwani Mohd
    Muhamad, Azira
    Shahidan, Muhammad Ashraf
    Yusof, Nurul Yuziana Mohd
    MARINE DRUGS, 2022, 20 (10)
  • [39] Molecular docking and molecular dynamics simulation studies of the interaction of anti-oral cancer plant Curcuma longa derived-compounds with human epidermal growth factor receptor 2
    Mfutu Mana Charly
    Jean-Paul Koto-Te-Nyiwa Ngbolua
    Jean-Paul Sekele Issouradi
    Emmanuel Kitete Mulongo
    Colette Masengo Ashande
    Jason Kilembe Thambwe
    Aristote Matondo
    Situakibanza Nani-Tuma Hippolyte
    Kamangu Ntambwe Erick
    Paul Bobe Alifi
    Nzudjom Foche Adelin
    Pius Tshimankinda Mpiana
    Journal of Proteins and Proteomics, 2024, 15 (3) : 491 - 507
  • [40] A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South
    D. Kelly
    L. Mc Sorley
    E. O’Shea
    E. Mc Carthy
    S. Bowe
    C. Brady
    J. Sui
    M. A. Dawod
    O. O’Brien
    D. Graham
    J. McCarthy
    L. Burke
    D. Power
    S. O’Reilly
    R. M. Bambury
    D. O. Mahony
    Irish Journal of Medical Science (1971 -), 2017, 186 : 855 - 857